BioPharma Dive
Patients who’d seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.
BioPharma Dive
Patients who'd seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.
BioPharma Dive
Patients who’d seen substantial hair regrowth in the first part of Nektar s trial had a deepening treatment response, extending a comeback bid that s caused shares to skyrocket over the last year.